Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Us Adults Aged >50 years

By: Sheryl A. Kluberg, Andrew L. Simon, Sarah M. Alam, Alexander Peters, Casie Horgan, Dongdong Li, Erick Moyneur, Elizabeth Messenger-Jones , Richard Platt, Cheryl N. McMahill-Walraven, Djeneba Audrey Djibo, Kimberly Daniels, Aziza Jamal-Alliale, Claire H. Pernar, Najat J. Ziyadeh Qianli Ma, Mano Selvan, O'Mareen Spence, Driss Oraichi, Harry Seifert, Huifeng Yun

Adult woman doctor sitting at table holding a tablet consulting a senior man

To assess whether recombinant zoster vaccine (RZV) is associated with an increased risk of new-onset gout among US adults aged ≥50 years.